Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment-Reference-Cited by-同舟云学术

Synthesis of Nirmatrelvir: Development of an Efficient, Scalable Process to Generate the Western Fragment

Published:2023-11-25 Issue:12 Volume:27 Page:2240-2249
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Algera Russell F.¹,Allais Christophe¹^ORCID,Baldwin Aaron F.²^ORCID,Becirovic Husein²,Bowles Paul¹,Brown Adam R.¹,Buske Jamie M.¹^ORCID,Clarke Hugh J.²,Do Nga M.¹,Doyle Kevin²,Fifer Jonathan¹,Gray Kaitlyn¹^ORCID,Happe Alan³,Hardink Mark²^ORCID,Hubbell Aran K.¹^ORCID,James Chintelle¹,Khadamkar Hrushikesh P.¹^ORCID,Magano Javier¹^ORCID,McInturff Emma L.¹^ORCID,Mustakis Jason¹^ORCID,Ozbuyukkaya Gizem¹,Piper Jared L.¹,Place David W.¹^ORCID,Ragan John A.¹^ORCID,Rauschenberger Blake¹,Reyes Giselle¹,Shehadeh Rawan²,Stanchina Corey¹,Stanley Michael³,Weekly R. Matthew¹,Weinstein Ethan¹,Weisenburger Gerald A.¹,Wood Ethan²,Yayla Hatice G.⁴,Yu Shu¹

Affiliation:

1. Chemical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

2. Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

3. Chemical Research and Development, Process Development Facility, Pfizer Worldwide Research and Development, Discovery Park, Sandwich, Kent CT13 9NJ, U.K.

4. Medicine Design, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

Funder

Pfizer

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.3c00249

Reference15 articles.

1. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

2. Owen, D. R.; Pettersson, M. Y.; Reese, M. R.; Sammons, M. F.; Tuttle, J. B.; Verhoest, P. R.; Wei, L.; Yang, Q.; Yang, X. Nitrile-Containing Antiviral Compounds. WO 2021250648 A1, 2021.

3. A 1-Pot Synthesis of the SARS-CoV-2 M^pro Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid

4. A sustainable synthesis of the SARS-CoV-2 Mpro inhibitor nirmatrelvir, the active ingredient in Paxlovid

5. Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions;European Journal of Medicinal Chemistry;2024-11

2. Nirmatrelvir: From Discovery to Modern and Alternative Synthetic Approaches;Processes;2024-06-17

3. Development of New Catalytic Asymmetric Routes toward a Cost-Driving Building Block of Nirmatrelvir;Organic Process Research & Development;2024-05-28

4. Reducing the cost of making drugs for low/limited-income countries by going green;Trends in Chemistry;2024-04

5. Synthesis of Nirmatrelvir: Development of a Scalable Cobalt-Catalyzed Cyclopropanation for Manufacture of the Bicyclic [3.1.0]Proline-Building Block;Organic Process Research & Development;2023-12-04